Christophe Arbet-Engels - Aug 31, 2023 Form 4 Insider Report for X4 Pharmaceuticals, Inc (XFOR)

Role
Chief Medical Officer
Signature
/s/ Adam S. Mostafa, attorney-in-fact
Stock symbol
XFOR
Transactions as of
Aug 31, 2023
Transactions value $
$1,600,000
Form type
4
Date filed
9/5/2023, 05:15 PM
Previous filing
Aug 16, 2023
Next filing
Feb 16, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction XFOR Stock Option (right to buy) Award $1.6M +1.25M $1.28 1.25M Aug 31, 2023 Common Stock 1.25M $1.28 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to the option shall vest on August 31, 2024, with the remainder vesting in equal installments of 2.0833% of the shares subject to the option each successive month thereafter for a period of 36 months, subject to the Reporting Person continuing to provide services through each such date.